Elanco Confirms NYSE Listing for Common Stock & Equity Units

TL;DR

**Elanco's stock and equity units are still trading on the NYSE, business as usual.**

AI Summary

Elanco Animal Health Inc. filed an 8-K on January 8, 2024, to disclose that its Common Stock and 5.00% Tangible Equity Units are both registered on the New York Stock Exchange under the trading symbols ELAN and ELAT, respectively. This filing primarily serves to update the public record regarding its listed securities, confirming their active trading status. For investors, this matters because it reaffirms the liquidity and transparency of Elanco's publicly traded securities, ensuring they can be easily bought and sold on a major exchange.

Why It Matters

This filing confirms the continued listing of Elanco's securities on the NYSE, which is crucial for maintaining investor confidence and ensuring market liquidity.

Risk Assessment

Risk Level: low — This filing is purely administrative, confirming existing listings, and introduces no new financial or operational risks.

Analyst Insight

This filing is purely informational, confirming existing market conditions. A smart investor would note the continued listing on a major exchange, which supports liquidity, but would not base investment decisions solely on this administrative update.

Key Players & Entities

• Elanco Animal Health Incorporated (company) — the registrant filing the 8-K
• New York Stock Exchange (company) — the exchange where Elanco's securities are registered
• ELAN (company) — trading symbol for Elanco's Common Stock
• ELAT (company) — trading symbol for Elanco's 5.00% Tangible Equity Units

FAQ

From the Filing

0001104659-24-002283.txt : 20240108 0001104659-24-002283.hdr.sgml : 20240108 20240108170027 ACCESSION NUMBER: 0001104659-24-002283 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 24520904 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm242357d1_8k.htm FORM 8-K false 0001739104 0001739104 2024-01-08 2024-01-08 0001739104 us-gaap:CommonStockMember 2024-01-08 2024-01-08 0001739104 elan:FivePercentTangibleEquityUnitsMember 2024-01-08 2024-01-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION W ashington , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): January 8, 2024   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Not Applicable (Former Name or Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange 5.00% Tangible Equity Units   ELAT   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨   Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 7.01 Regulation FD.   On January 9, 2024, Elanco Animal Health Incorporated (the “Company”) will present at the 42 nd Annual J.P. Morgan Healthcare Conference (the “JPM Conference”). A copy of the Company’s presentation is furnished as Exhibit 99.1.   The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deem